Global Pegylated Proteins

Pegylated Proteins Comprehensive Study by Type (Colony Stimulating Factor, Interferon, Erythropoietin (EPO), Recombinant Factor VIII, Monoclonal Antibody, Enzyme, Others), Application (Cancer, Autoimmune Disease, Hepatitis, Multiple Sclerosis, Hemophilia, Gastrointestinal Disorder, Others) Players and Region - Global Market Outlook to 2027

Pegylated Proteins Market by XX Submarkets | Forecast Years 2022-2027 | CAGR: 9.8%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
PEGylation is the method of attaching polyethylene glycol polymer chains to molecules, such as a drug, therapeutic protein, or vesicle, by covalent and non-covalent means. By changing the electrostatic binding, validation, and hydrophobicity of the molecule, PEGylation increases drug stability and solubility while lowering immunogenicity. PEGylation has been applied to a wide range of proteins, therapeutic peptides, and small drug molecules in order to enhance or change pharmacokinetic parameters and reap different benefits. The rising prevalence of chronic diseases such as cancer, kidney disease, and rheumatoid arthritis is a major factor driving market development. The creation of various therapeutics for the treatment of chronic kidney disease based on PEGylated proteins is a hot topic these days. Furthermore, biotechnology and pharmaceutical companies are increasing their investments in research and development projects, which is fueling business growth. Protein-based drugs are increasingly being preferred over non-protein-based drugs because pegylation improves protein circulation and half-life, thus enhancing efficacy.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)
Key Companies ProfiledMerck KGaA (Germany), Thermo Fisher Scientific (United States), Celares GmbH (Germany), Astrazeneca plc (United Kingdom), Pfizer Inc. (United States), Biogen inc (United States), F. Hoffmann-La Roche Ltd (Switzerland), Horizon Pharma plc (Ireland), Shire plc (United States) and Quiapeg Pharmaceuticals Holding Ab (Sweden)
CAGR9.8%


According to AMA, the market for Pegylated Proteins is expected to register a CAGR of 9.8% during the forecast period to 2027. This growth is primarily driven by High Prevalence of Chronic Diseases and Advantages offered by PEGylation.

Globally, a noticeable market trend is evident Growth in Adoption of PEGylated Protein Therapeutics. The Telecom Services sector in the North America region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Merck KGaA (Germany), Thermo Fisher Scientific (United States), Celares GmbH (Germany), Astrazeneca plc (United Kingdom), Pfizer Inc. (United States), Biogen inc (United States), F. Hoffmann-La Roche Ltd (Switzerland), Horizon Pharma plc (Ireland), Shire plc (United States) and Quiapeg Pharmaceuticals Holding Ab (Sweden) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

In August 2021, JenKem Technology provides large scale GMP manufacture of PEG derivatives for Lipid Nanoparticles (LNPs), and related PEG intermediates., In July 2021, JenKem Technology offers kilogram scale manufacture (5Kg per batch and more) of PEG and Monodisperse PEG Azide Derivatives with high purity (95%), in both GMP and non-GMP grade. and August 2020- Cadila Healthcare Limited initiated the phase II, multicenter, open-label, randomized, comparator-controlled study to evaluate the efficacy and safety of PEGylated Interferon -α2b in the treatment of adult patients diagnosed with SARS-CoV2 (COVID-19).

Market Drivers
  • High Prevalence of Chronic Diseases
  • Advantages offered by PEGylation

Market Trend
  • Growth in Adoption of PEGylated Protein Therapeutics

Restraints
  • Drug Failures and Drug Recall
  • High Costs Associated with Drug Development

Opportunities
Rise in Research and Development Funding by Key Players
Challenges
Current Lack of Awareness and Stringent Regulatory Factors

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Pegylated Proteins Study Sheds Light on
— The Pegylated Proteins Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Pegylated Proteins industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Pegylated Proteins industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Colony Stimulating Factor
  • Interferon
  • Erythropoietin (EPO)
  • Recombinant Factor VIII
  • Monoclonal Antibody
  • Enzyme
  • Others
By Application
  • Cancer
  • Autoimmune Disease
  • Hepatitis
  • Multiple Sclerosis
  • Hemophilia
  • Gastrointestinal Disorder
  • Others
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. High Prevalence of Chronic Diseases
      • 3.2.2. Advantages offered by PEGylation
    • 3.3. Market Challenges
      • 3.3.1. Current Lack of Awareness
      • 3.3.2. Stringent Regulatory Factors
    • 3.4. Market Trends
      • 3.4.1. Growth in Adoption of PEGylated Protein Therapeutics
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Pegylated Proteins, by Type, Application and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Pegylated Proteins (Value)
      • 5.2.1. Global Pegylated Proteins by: Type (Value)
        • 5.2.1.1. Colony Stimulating Factor
        • 5.2.1.2. Interferon
        • 5.2.1.3. Erythropoietin (EPO)
        • 5.2.1.4. Recombinant Factor VIII
        • 5.2.1.5. Monoclonal Antibody
        • 5.2.1.6. Enzyme
        • 5.2.1.7. Others
      • 5.2.2. Global Pegylated Proteins by: Application (Value)
        • 5.2.2.1. Cancer
        • 5.2.2.2. Autoimmune Disease
        • 5.2.2.3. Hepatitis
        • 5.2.2.4. Multiple Sclerosis
        • 5.2.2.5. Hemophilia
        • 5.2.2.6. Gastrointestinal Disorder
        • 5.2.2.7. Others
      • 5.2.3. Global Pegylated Proteins Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Pegylated Proteins: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merck KGaA (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Thermo Fisher Scientific (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Celares GmbH (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Astrazeneca plc (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Biogen inc (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Horizon Pharma plc (Ireland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Shire plc (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Quiapeg Pharmaceuticals Holding Ab (Sweden)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Pegylated Proteins Sale, by Type, Application and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Pegylated Proteins (Value)
      • 7.2.1. Global Pegylated Proteins by: Type (Value)
        • 7.2.1.1. Colony Stimulating Factor
        • 7.2.1.2. Interferon
        • 7.2.1.3. Erythropoietin (EPO)
        • 7.2.1.4. Recombinant Factor VIII
        • 7.2.1.5. Monoclonal Antibody
        • 7.2.1.6. Enzyme
        • 7.2.1.7. Others
      • 7.2.2. Global Pegylated Proteins by: Application (Value)
        • 7.2.2.1. Cancer
        • 7.2.2.2. Autoimmune Disease
        • 7.2.2.3. Hepatitis
        • 7.2.2.4. Multiple Sclerosis
        • 7.2.2.5. Hemophilia
        • 7.2.2.6. Gastrointestinal Disorder
        • 7.2.2.7. Others
      • 7.2.3. Global Pegylated Proteins Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Pegylated Proteins: by Type(USD Million)
  • Table 2. Pegylated Proteins Colony Stimulating Factor , by Region USD Million (2016-2021)
  • Table 3. Pegylated Proteins Interferon , by Region USD Million (2016-2021)
  • Table 4. Pegylated Proteins Erythropoietin (EPO) , by Region USD Million (2016-2021)
  • Table 5. Pegylated Proteins Recombinant Factor VIII , by Region USD Million (2016-2021)
  • Table 6. Pegylated Proteins Monoclonal Antibody , by Region USD Million (2016-2021)
  • Table 7. Pegylated Proteins Enzyme , by Region USD Million (2016-2021)
  • Table 8. Pegylated Proteins Others , by Region USD Million (2016-2021)
  • Table 9. Pegylated Proteins: by Application(USD Million)
  • Table 10. Pegylated Proteins Cancer , by Region USD Million (2016-2021)
  • Table 11. Pegylated Proteins Autoimmune Disease , by Region USD Million (2016-2021)
  • Table 12. Pegylated Proteins Hepatitis , by Region USD Million (2016-2021)
  • Table 13. Pegylated Proteins Multiple Sclerosis , by Region USD Million (2016-2021)
  • Table 14. Pegylated Proteins Hemophilia , by Region USD Million (2016-2021)
  • Table 15. Pegylated Proteins Gastrointestinal Disorder , by Region USD Million (2016-2021)
  • Table 16. Pegylated Proteins Others , by Region USD Million (2016-2021)
  • Table 17. South America Pegylated Proteins, by Country USD Million (2016-2021)
  • Table 18. South America Pegylated Proteins, by Type USD Million (2016-2021)
  • Table 19. South America Pegylated Proteins, by Application USD Million (2016-2021)
  • Table 20. Brazil Pegylated Proteins, by Type USD Million (2016-2021)
  • Table 21. Brazil Pegylated Proteins, by Application USD Million (2016-2021)
  • Table 22. Argentina Pegylated Proteins, by Type USD Million (2016-2021)
  • Table 23. Argentina Pegylated Proteins, by Application USD Million (2016-2021)
  • Table 24. Rest of South America Pegylated Proteins, by Type USD Million (2016-2021)
  • Table 25. Rest of South America Pegylated Proteins, by Application USD Million (2016-2021)
  • Table 26. Asia Pacific Pegylated Proteins, by Country USD Million (2016-2021)
  • Table 27. Asia Pacific Pegylated Proteins, by Type USD Million (2016-2021)
  • Table 28. Asia Pacific Pegylated Proteins, by Application USD Million (2016-2021)
  • Table 29. China Pegylated Proteins, by Type USD Million (2016-2021)
  • Table 30. China Pegylated Proteins, by Application USD Million (2016-2021)
  • Table 31. Japan Pegylated Proteins, by Type USD Million (2016-2021)
  • Table 32. Japan Pegylated Proteins, by Application USD Million (2016-2021)
  • Table 33. India Pegylated Proteins, by Type USD Million (2016-2021)
  • Table 34. India Pegylated Proteins, by Application USD Million (2016-2021)
  • Table 35. South Korea Pegylated Proteins, by Type USD Million (2016-2021)
  • Table 36. South Korea Pegylated Proteins, by Application USD Million (2016-2021)
  • Table 37. Taiwan Pegylated Proteins, by Type USD Million (2016-2021)
  • Table 38. Taiwan Pegylated Proteins, by Application USD Million (2016-2021)
  • Table 39. Australia Pegylated Proteins, by Type USD Million (2016-2021)
  • Table 40. Australia Pegylated Proteins, by Application USD Million (2016-2021)
  • Table 41. Rest of Asia-Pacific Pegylated Proteins, by Type USD Million (2016-2021)
  • Table 42. Rest of Asia-Pacific Pegylated Proteins, by Application USD Million (2016-2021)
  • Table 43. Europe Pegylated Proteins, by Country USD Million (2016-2021)
  • Table 44. Europe Pegylated Proteins, by Type USD Million (2016-2021)
  • Table 45. Europe Pegylated Proteins, by Application USD Million (2016-2021)
  • Table 46. Germany Pegylated Proteins, by Type USD Million (2016-2021)
  • Table 47. Germany Pegylated Proteins, by Application USD Million (2016-2021)
  • Table 48. France Pegylated Proteins, by Type USD Million (2016-2021)
  • Table 49. France Pegylated Proteins, by Application USD Million (2016-2021)
  • Table 50. Italy Pegylated Proteins, by Type USD Million (2016-2021)
  • Table 51. Italy Pegylated Proteins, by Application USD Million (2016-2021)
  • Table 52. United Kingdom Pegylated Proteins, by Type USD Million (2016-2021)
  • Table 53. United Kingdom Pegylated Proteins, by Application USD Million (2016-2021)
  • Table 54. Netherlands Pegylated Proteins, by Type USD Million (2016-2021)
  • Table 55. Netherlands Pegylated Proteins, by Application USD Million (2016-2021)
  • Table 56. Rest of Europe Pegylated Proteins, by Type USD Million (2016-2021)
  • Table 57. Rest of Europe Pegylated Proteins, by Application USD Million (2016-2021)
  • Table 58. MEA Pegylated Proteins, by Country USD Million (2016-2021)
  • Table 59. MEA Pegylated Proteins, by Type USD Million (2016-2021)
  • Table 60. MEA Pegylated Proteins, by Application USD Million (2016-2021)
  • Table 61. Middle East Pegylated Proteins, by Type USD Million (2016-2021)
  • Table 62. Middle East Pegylated Proteins, by Application USD Million (2016-2021)
  • Table 63. Africa Pegylated Proteins, by Type USD Million (2016-2021)
  • Table 64. Africa Pegylated Proteins, by Application USD Million (2016-2021)
  • Table 65. North America Pegylated Proteins, by Country USD Million (2016-2021)
  • Table 66. North America Pegylated Proteins, by Type USD Million (2016-2021)
  • Table 67. North America Pegylated Proteins, by Application USD Million (2016-2021)
  • Table 68. United States Pegylated Proteins, by Type USD Million (2016-2021)
  • Table 69. United States Pegylated Proteins, by Application USD Million (2016-2021)
  • Table 70. Canada Pegylated Proteins, by Type USD Million (2016-2021)
  • Table 71. Canada Pegylated Proteins, by Application USD Million (2016-2021)
  • Table 72. Mexico Pegylated Proteins, by Type USD Million (2016-2021)
  • Table 73. Mexico Pegylated Proteins, by Application USD Million (2016-2021)
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Company Basic Information, Sales Area and Its Competitors
  • Table 79. Company Basic Information, Sales Area and Its Competitors
  • Table 80. Company Basic Information, Sales Area and Its Competitors
  • Table 81. Company Basic Information, Sales Area and Its Competitors
  • Table 82. Company Basic Information, Sales Area and Its Competitors
  • Table 83. Company Basic Information, Sales Area and Its Competitors
  • Table 84. Pegylated Proteins: by Type(USD Million)
  • Table 85. Pegylated Proteins Colony Stimulating Factor , by Region USD Million (2022-2027)
  • Table 86. Pegylated Proteins Interferon , by Region USD Million (2022-2027)
  • Table 87. Pegylated Proteins Erythropoietin (EPO) , by Region USD Million (2022-2027)
  • Table 88. Pegylated Proteins Recombinant Factor VIII , by Region USD Million (2022-2027)
  • Table 89. Pegylated Proteins Monoclonal Antibody , by Region USD Million (2022-2027)
  • Table 90. Pegylated Proteins Enzyme , by Region USD Million (2022-2027)
  • Table 91. Pegylated Proteins Others , by Region USD Million (2022-2027)
  • Table 92. Pegylated Proteins: by Application(USD Million)
  • Table 93. Pegylated Proteins Cancer , by Region USD Million (2022-2027)
  • Table 94. Pegylated Proteins Autoimmune Disease , by Region USD Million (2022-2027)
  • Table 95. Pegylated Proteins Hepatitis , by Region USD Million (2022-2027)
  • Table 96. Pegylated Proteins Multiple Sclerosis , by Region USD Million (2022-2027)
  • Table 97. Pegylated Proteins Hemophilia , by Region USD Million (2022-2027)
  • Table 98. Pegylated Proteins Gastrointestinal Disorder , by Region USD Million (2022-2027)
  • Table 99. Pegylated Proteins Others , by Region USD Million (2022-2027)
  • Table 100. South America Pegylated Proteins, by Country USD Million (2022-2027)
  • Table 101. South America Pegylated Proteins, by Type USD Million (2022-2027)
  • Table 102. South America Pegylated Proteins, by Application USD Million (2022-2027)
  • Table 103. Brazil Pegylated Proteins, by Type USD Million (2022-2027)
  • Table 104. Brazil Pegylated Proteins, by Application USD Million (2022-2027)
  • Table 105. Argentina Pegylated Proteins, by Type USD Million (2022-2027)
  • Table 106. Argentina Pegylated Proteins, by Application USD Million (2022-2027)
  • Table 107. Rest of South America Pegylated Proteins, by Type USD Million (2022-2027)
  • Table 108. Rest of South America Pegylated Proteins, by Application USD Million (2022-2027)
  • Table 109. Asia Pacific Pegylated Proteins, by Country USD Million (2022-2027)
  • Table 110. Asia Pacific Pegylated Proteins, by Type USD Million (2022-2027)
  • Table 111. Asia Pacific Pegylated Proteins, by Application USD Million (2022-2027)
  • Table 112. China Pegylated Proteins, by Type USD Million (2022-2027)
  • Table 113. China Pegylated Proteins, by Application USD Million (2022-2027)
  • Table 114. Japan Pegylated Proteins, by Type USD Million (2022-2027)
  • Table 115. Japan Pegylated Proteins, by Application USD Million (2022-2027)
  • Table 116. India Pegylated Proteins, by Type USD Million (2022-2027)
  • Table 117. India Pegylated Proteins, by Application USD Million (2022-2027)
  • Table 118. South Korea Pegylated Proteins, by Type USD Million (2022-2027)
  • Table 119. South Korea Pegylated Proteins, by Application USD Million (2022-2027)
  • Table 120. Taiwan Pegylated Proteins, by Type USD Million (2022-2027)
  • Table 121. Taiwan Pegylated Proteins, by Application USD Million (2022-2027)
  • Table 122. Australia Pegylated Proteins, by Type USD Million (2022-2027)
  • Table 123. Australia Pegylated Proteins, by Application USD Million (2022-2027)
  • Table 124. Rest of Asia-Pacific Pegylated Proteins, by Type USD Million (2022-2027)
  • Table 125. Rest of Asia-Pacific Pegylated Proteins, by Application USD Million (2022-2027)
  • Table 126. Europe Pegylated Proteins, by Country USD Million (2022-2027)
  • Table 127. Europe Pegylated Proteins, by Type USD Million (2022-2027)
  • Table 128. Europe Pegylated Proteins, by Application USD Million (2022-2027)
  • Table 129. Germany Pegylated Proteins, by Type USD Million (2022-2027)
  • Table 130. Germany Pegylated Proteins, by Application USD Million (2022-2027)
  • Table 131. France Pegylated Proteins, by Type USD Million (2022-2027)
  • Table 132. France Pegylated Proteins, by Application USD Million (2022-2027)
  • Table 133. Italy Pegylated Proteins, by Type USD Million (2022-2027)
  • Table 134. Italy Pegylated Proteins, by Application USD Million (2022-2027)
  • Table 135. United Kingdom Pegylated Proteins, by Type USD Million (2022-2027)
  • Table 136. United Kingdom Pegylated Proteins, by Application USD Million (2022-2027)
  • Table 137. Netherlands Pegylated Proteins, by Type USD Million (2022-2027)
  • Table 138. Netherlands Pegylated Proteins, by Application USD Million (2022-2027)
  • Table 139. Rest of Europe Pegylated Proteins, by Type USD Million (2022-2027)
  • Table 140. Rest of Europe Pegylated Proteins, by Application USD Million (2022-2027)
  • Table 141. MEA Pegylated Proteins, by Country USD Million (2022-2027)
  • Table 142. MEA Pegylated Proteins, by Type USD Million (2022-2027)
  • Table 143. MEA Pegylated Proteins, by Application USD Million (2022-2027)
  • Table 144. Middle East Pegylated Proteins, by Type USD Million (2022-2027)
  • Table 145. Middle East Pegylated Proteins, by Application USD Million (2022-2027)
  • Table 146. Africa Pegylated Proteins, by Type USD Million (2022-2027)
  • Table 147. Africa Pegylated Proteins, by Application USD Million (2022-2027)
  • Table 148. North America Pegylated Proteins, by Country USD Million (2022-2027)
  • Table 149. North America Pegylated Proteins, by Type USD Million (2022-2027)
  • Table 150. North America Pegylated Proteins, by Application USD Million (2022-2027)
  • Table 151. United States Pegylated Proteins, by Type USD Million (2022-2027)
  • Table 152. United States Pegylated Proteins, by Application USD Million (2022-2027)
  • Table 153. Canada Pegylated Proteins, by Type USD Million (2022-2027)
  • Table 154. Canada Pegylated Proteins, by Application USD Million (2022-2027)
  • Table 155. Mexico Pegylated Proteins, by Type USD Million (2022-2027)
  • Table 156. Mexico Pegylated Proteins, by Application USD Million (2022-2027)
  • Table 157. Research Programs/Design for This Report
  • Table 158. Key Data Information from Secondary Sources
  • Table 159. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Pegylated Proteins: by Type USD Million (2016-2021)
  • Figure 5. Global Pegylated Proteins: by Application USD Million (2016-2021)
  • Figure 6. South America Pegylated Proteins Share (%), by Country
  • Figure 7. Asia Pacific Pegylated Proteins Share (%), by Country
  • Figure 8. Europe Pegylated Proteins Share (%), by Country
  • Figure 9. MEA Pegylated Proteins Share (%), by Country
  • Figure 10. North America Pegylated Proteins Share (%), by Country
  • Figure 11. Global Pegylated Proteins share by Players 2021 (%)
  • Figure 12. Global Pegylated Proteins share by Players (Top 3) 2021(%)
  • Figure 13. Global Pegylated Proteins share by Players (Top 5) 2021(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 16. Merck KGaA (Germany) Revenue: by Geography 2021
  • Figure 17. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 18. Thermo Fisher Scientific (United States) Revenue: by Geography 2021
  • Figure 19. Celares GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 20. Celares GmbH (Germany) Revenue: by Geography 2021
  • Figure 21. Astrazeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 22. Astrazeneca plc (United Kingdom) Revenue: by Geography 2021
  • Figure 23. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Pfizer Inc. (United States) Revenue: by Geography 2021
  • Figure 25. Biogen inc (United States) Revenue, Net Income and Gross profit
  • Figure 26. Biogen inc (United States) Revenue: by Geography 2021
  • Figure 27. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 28. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2021
  • Figure 29. Horizon Pharma plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 30. Horizon Pharma plc (Ireland) Revenue: by Geography 2021
  • Figure 31. Shire plc (United States) Revenue, Net Income and Gross profit
  • Figure 32. Shire plc (United States) Revenue: by Geography 2021
  • Figure 33. Quiapeg Pharmaceuticals Holding Ab (Sweden) Revenue, Net Income and Gross profit
  • Figure 34. Quiapeg Pharmaceuticals Holding Ab (Sweden) Revenue: by Geography 2021
  • Figure 35. Global Pegylated Proteins: by Type USD Million (2022-2027)
  • Figure 36. Global Pegylated Proteins: by Application USD Million (2022-2027)
  • Figure 37. South America Pegylated Proteins Share (%), by Country
  • Figure 38. Asia Pacific Pegylated Proteins Share (%), by Country
  • Figure 39. Europe Pegylated Proteins Share (%), by Country
  • Figure 40. MEA Pegylated Proteins Share (%), by Country
  • Figure 41. North America Pegylated Proteins Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Merck KGaA (Germany)
  • Thermo Fisher Scientific (United States)
  • Celares GmbH (Germany)
  • Astrazeneca plc (United Kingdom)
  • Pfizer Inc. (United States)
  • Biogen inc (United States)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Horizon Pharma plc (Ireland)
  • Shire plc (United States)
  • Quiapeg Pharmaceuticals Holding Ab (Sweden)
Additional players considered in the study are as follows:
NOF America Corporation (United States) , Quanta BioDesign, Ltd (United States) , JenKem Technology USA, Inc. (United States)
Select User Access Type

Key Highlights of Report


May 2022 204 Pages 60 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Pegylated Proteins Quantitative research analysis
Global Pegylated Proteins Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Pegylated Proteins market is expected to see a CAGR of 9.8% during projected year 2021 to 2027.
Top performing companies in the Global Pegylated Proteins market are Merck KGaA (Germany), Thermo Fisher Scientific (United States), Celares GmbH (Germany), Astrazeneca plc (United Kingdom), Pfizer Inc. (United States), Biogen inc (United States), F. Hoffmann-La Roche Ltd (Switzerland), Horizon Pharma plc (Ireland), Shire plc (United States) and Quiapeg Pharmaceuticals Holding Ab (Sweden), to name a few.
North America is dominating the Pegylated Proteins Market.

Know More About Global Pegylated Proteins Report?

Have a Query? Click Here

Other Related Reports

Medical Plastic Compounds Comprehensive Study by Type (Polyvinylchloride, Polyethylene, Polypropylene, Polystyrene, Polyester, Polycarbonate, Polyurethane, Acrylics, Others), Application (Disposables...
$ 3800
Digital Payment Solutions Comprehensive Study by Platform (Web-based, Mobile-based), Technology (Near Field Communication (NFC), QR Code Payments, Biometric Authentication, Blockchain-based Payments,...
$ 3800
Distributed Solar Pv Comprehensive Study by Type (Antifreeze, Coolant, Brake Fluid, Lubricating Oil, Additive, Other), Application (Commercial Use, Individual Use), Grid (Grid-tied, Grid/hybrid, Off-...
$ 3800
Enterprise Infrastructure Servers Comprehensive Study by Type (Linux System Type, Windows System Type, UNIX System Type, Others), Application (IT & Telecommunications, BFSI, Manufacturing, Retail, He...
$ 3750
HVAC Software Comprehensive Study by Deployment Mode (Cloud-Based, Web-Based), Organization Size (Large Enterprises, SMEs), OS Support (Windows, Mac, Android) Players and Region - Global Market Outlo...
$ 3500
Media Monitoring Software Comprehensive Study by Type (Broadcast Monitoring, Social Media Monitoring, Online Monitoring, Print Monitoring), Deployment Mode (Cloud-Based, On-Premises), Industry Vertic...
$ 3750